Annals of Oncology

Papers
(The H4-Index of Annals of Oncology is 91. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sid1033
Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu936
1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients873
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?697
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial693
588P Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial666
111P A study on the relationship between tumor fusion burden (TFB) and tumor immune microenvironment586
118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella489
140P Benefit of adjuvant chemotherapy in luminal A-like early breast cancer in women aged 40 years or younger: Results of a national multi-institutional study460
1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)434
P-111 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model422
801P Response to first-line platinum chemotherapy in microsatellite instability high (MSI-H) metastatic endometrial carcinoma418
839P Physician considered treatment attributes for third-line diffuse-large B-cell lymphoma treatment decision-making: Physician perspectives from a survey across Western Europe and US415
31P Sulfhydryl groups in estrogen receptors394
1803P The differences of TMB scores could be found in patients with different tumor types or pathological types394
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data389
Notice and Disclaimer363
P-362 Retrospective analysis of metastatic colorectal cancer based on clinical cancer registry data. Tumor biology, treatment, and outcome321
P-379 ARID1A as a prognostic biomarker in gastroesophageal cancer: A genomic database analysis312
1692P Thromboprophylaxis in high-risk oncology patients: Is it a safe and effective clinical decision-intervention?304
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study301
1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study299
1483P Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer296
1482P Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients294
404P Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India260
1481P Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status248
50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients236
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience229
461P Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India227
720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence220
1583P COVID-19 related risk in patients enrolled in early-phase clinical trials219
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)213
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial dis210
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study209
70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry198
P-404 Survival outcomes and prognostic factors in high risk locally advanced rectal cancers (LARC) undergoing concurrent capecitabine and long course radiation (Cape – RT) – results of a large cohort 196
39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients194
651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)194
677P Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials183
P-160 Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up180
355P Butterfly glioblastoma: Treatment strategies and clinical outcome180
CN14 Cancer prevention awareness among Croatian AYA population178
CN28 Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization171
P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis168
83TiP Clinical implications of clonal hematopoiesis mutations in patients with solid tumors166
P-177 Sex differences in chemotherapy-induced toxicities in gastric cancer patients165
Journal Information164
P-184 Prognostic value of mTOR expression and mismatch repair gene profile in advanced gastric and gastro-oesophageal cancer162
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients160
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies159
1012P Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade159
137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors154
139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal152
202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibito152
O7-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16147
37P Development of splice switching antisense oligonucleotides targeting midkine146
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy146
121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data145
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1144
140P Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience142
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study141
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy136
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation133
Title Page133
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis130
12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer130
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer126
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the 125
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data125
554P Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study120
1627P Management of locally advanced rectal cancer during the COVID-19 outbreak: First results of a shift towards short course neoadjuvant radiotherapy118
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized tria118
MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors115
1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment113
350P Primary prevention of chemotherapy-induced neutropenia in patients with advanced lung cancer in real-world research113
1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic113
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)112
1133P Whole genome sequencing can classify diagnostically challenging tumors109
1485O Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study107
373P Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2106
MO45-3 The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion106
44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas105
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity104
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene101
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy99
470P Genomic landscape and its correlations with immunotherapy-related biomarkers in Chinese colorectal cancer patients97
SY12-3 Precision medicine for esophageal cancer94
1704P Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration94
1233P EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation94
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress94
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches94
0.037152051925659